These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10204653

  • 21. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 22. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Jun; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 23. Lipids in type 2 diabetes.
    Laakso M.
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [Abstract] [Full Text] [Related]

  • 24. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 25. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 26. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 27. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 28. Cholesterol lipoproteins, triglycerides, rural-urban differences and prevalence of dyslipidaemia among males in Rajasthan.
    Gupta R, Prakash H, Kaul V.
    J Assoc Physicians India; 1997 Apr 04; 45(4):275-9. PubMed ID: 12521083
    [Abstract] [Full Text] [Related]

  • 29. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 04; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO, Jorgensen M, Kirschenbaum J, Sparks C, Zeigler L, Albertson BD.
    Am J Med; 2008 Jul 04; 121(7):604-10. PubMed ID: 18538295
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov 04; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 35. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.
    Arterioscler Thromb Vasc Biol; 2008 Jun 04; 28(6):1172-8. PubMed ID: 18356553
    [Abstract] [Full Text] [Related]

  • 36. The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder.
    Kotani K, Koibuchi H, Yamada T, Taniguchi N.
    Clin Chim Acta; 2009 Nov 04; 409(1-2):67-9. PubMed ID: 19723514
    [Abstract] [Full Text] [Related]

  • 37. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan 04; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 38. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV, Rozhkova TA, Kotova LA, Tvorogova MG, Semenova OA.
    Ter Arkh; 1996 Jan 04; 68(6):58-61. PubMed ID: 8771689
    [Abstract] [Full Text] [Related]

  • 39. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV, Tvorogova MG, Arabidze GG, Kukharchuk VV.
    Ter Arkh; 1998 Jan 04; 70(9):57-61. PubMed ID: 9821228
    [Abstract] [Full Text] [Related]

  • 40. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul 04; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.